Dopamine receptors, motor responses, and dopaminergic agonists

Neurologist

Volumn 17, Issue 6 SUPPL., 2011, Pages

  Luquin Piudo, M Rosario ^a   Sanz, Pilar ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

Author keywords

dopamine agonists; Dopamine receptors; Parkinson disease; signaling pathways

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ADENYLATE CYCLASE; AMANTADINE; APOMORPHINE; ARACHIDONIC ACID; BROMOCRIPTINE; CABERGOLINE; CALCIUM ION; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; LEVODOPA; LISURIDE; MESSENGER RNA; PERGOLIDE; PHOSPHATIDYLINOSITIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; U 91356A; UNCLASSIFIED DRUG;

ADDICTION; ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DENERVATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DYSKINESIA; EDEMA; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HALLUCINATION; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LIPID METABOLISM; LONG TERM CARE; MOTOR ACTIVITY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSYCHOSIS; SIGNAL TRANSDUCTION; SLEEP DISORDER; SOMNOLENCE;

ADENYLATE CYCLASE; ANTIPARKINSON AGENTS; ARACHIDONIC ACID; CALCIUM CHANNELS; DOPAMINE; DOPAMINE AGONISTS; GTP-BINDING PROTEINS; HUMANS; LEVODOPA; MOTOR ACTIVITY; PARKINSON DISEASE; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE;

EID: 80455158108     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3182396688     Document Type: Article

References (59)

1. Jackson DM, Westlind-Danielsson A. Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol Ther. 1994;64:291-370.
2. Kandel ERSJ, Jessel TM. Principles of Neural Sciences. 3rd ed. New York: Appelton and Lange; 1991.
3. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24: 165-205.
4. Bourne HR. How receptors talk to trimeric G proteins. Curr Opin Cell Biol. 1997;9:134-142.
5. Bourne HR. G proteins: The arginine finger strikes again. Nature. 1997;389:673-674.
6. Grandy DK, Civelli O. G-protein-coupled receptors: The new dopamine receptor subtypes. Curr Opin Neurobiol. 1992;2:275-281.
7. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci. 2001;2:274-286.
8. Chen JJ, Swope DM, Dastipour K, et al. Transdermal rotigotine a clinically innonvative doapmine-receptor agonist for the treatment of Parkinson disease. Pharmacotheraphy. 2009;29:1452-1467.
9. Tesmer JJ, The quest to understand heterotrimeric G protein signaling. Nat Struct Mol Biol. 2010;17:650-652.
10. Bockaert J, Perroy J, Becamel C, et al. GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol. 2010;50:89-109.
11. Heitzler D, Crepieux P, Poupon A, et al. Towards a systems biology approach of G protein-coupled receptor signalling: challenges and expectations. C R Biol. 2009;332:947-957.
12. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277:93-96.
13. Martres MP, Sokoloff P, Giros B, et al. Dopaminergic receptors, multiple targets for neuroleptics. Ann Med Psychol (Paris). 1992;150:119-123.
14. Zhou QY, Grandy DK, Thambi L, et al. Cloning and expression of human and rat D1 dopamine receptors. Nature. 1990;347:76-80.
15. Horn F, van der Wenden EM, Oliveira L, et al. Receptors coupling to G proteins: Is there a signal behind the sequence? Proteins. 2000;41:448-459.
16. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: From structure to function. Physiol Rev. 1998;78:189-225.
17. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991;350:610-614.
18. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991;350:614-619.
19. Muly EC, Senyuz M, Khan ZU, et al. Distribution of D1 and D5 dopamine receptors in the primate and rat basolateral amygdala. Brain Struct Funct. 2009;213:375-393.
20. Kliem MA, Pare JF, Khan ZU, et al. Comparative ultrastructural analysis of D1 and D5 dopamine receptor distribution in the substantia nigra and globus pallidus of monkeys. Adv Behav Biol. 2009;58:239-253.
21. Rani M, Kanungo MS. Expression of D2 dopamine receptor in the mouse brain. Biochem Biophys Res Commun. 2006;344:981-986.
22. O'Dowd BF. Structures of dopamine receptors. J Neurochem. 1993;60:804-816.
23. Mengod G, Villaro MT, Landwehrmeyer GB, et al. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int. 1992;20(Suppl):33S-43S.
24. Marazziti D, Lucacchini A, Baroni S, et al. Presence of D4 dopamine receptors in human prefrontal cortex: A postmortem study. Rev Bras Psiquiatr. 2007;29:148-152.
25. Wong AH, Van Tol HH. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1091-1099.
26. Oak JN, Oldenhof J, Van Tol HH. The dopamine D(4) receptor: One decade of research. Eur J Pharmacol. 2000;405:303-327.
27. Monsma FJ Jr, Mahan LC, McVittie LD, et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A. 1990;87:6723-6727.
28. Choi EJ, Xia Z, Villacres EC, et al. The regulatory diversity of the mammalian adenylyl cyclases. Curr Opin Cell Biol. 1993;5: 269-273.
29. Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci. 1994;17:399-418.
30. Braun AP, Schulman H. The multifunctional calcium/calmodulindependent protein kinase: From form to function. Annu Rev Physiol. 1995;57:417-445.
31. Eguiagaray JG, Egea J, Bravo-Cordero JJ, et al. Neurotransmitters, calcium signalling and neuronal communication. Neurocirugia (Astur). 2004;15:109-118.
32. Groves JT, Kuriyan J. Molecular mechanisms in signal transduction at the membrane. Nat Struct Mol Biol. 2010;17:659-665.
33. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson'sdisease patients with and without dyskinesias. Neurology. 1997;49:717-723.
34. Guigoni C, Doudnikoff E, Li Q, et al. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis. 2007;26:452-463.
35. Pioli E, Sohr R, Meissner W, et al. Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex. Neurochem Int. 2004;45:995-1004.
36. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned macaque model of Parkinson's disease. J Neurosci. 2001;21:6853-6861.
37. Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord. 1998;13:788-797.
38. Nagai Y, Ueno S, Saeki Y, et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 1996;46:791-795.
39. Hurley MJ, Stubbs CM, Jenner P, et al. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett. 1996;214:75-78.
40. Hurley MJ, Jolkkonen J, Stubbs CM, et al. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 1996;709:259-264.
41. Graham WC, Sambrook MA, Crossman AR. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 1993;602:290-303.
42. Rioux L, Frohna PA, Joyce JN, et al. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord. 1997;12:148-158.
43. Berthet A, Bezard E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord. 2009;15(Suppl 4):S8-12.
44. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med. 2003;9:762-767.
45. Muriel MP, Orieux G, Hirsch EC. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord. 2002;17:1174-1179.
46. Muriel MP, Bernard V, Levey AI, et al. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol. 1999;46: 103-111.
47. Gagnon C, Bedard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol. 1990;178:115-120.
48. Goulet M, Morissette M, Calon F, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis. Neuroscience. 1997; 79:497-507.
49. Goulet M, Grondin R, Blanchet PJ, et al. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res. 1996;719:129-137.
50. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther. 2001;90:231-259.
51. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. 1999;100:163-167.
52. Poewe W. Psychosis in Parkinson's disease. Mov Disord. 2003;18(Suppl 6):S80-S87.
53. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology. 1999;53:364-370.
54. Fox SH, Visanji NP, Johnston TH, et al. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol. 2006;63:1343-1344.
55. Gschwandtner U, Aston J, Renaud S, et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol. 2001; 24:170-172.
56. Pontone G, Williams JR, Bassett SS, et al. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258-1261.
57. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66:1750-1752.
58. Garcia RF, Ordacgi L, Mendlowicz MV, et al. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling. Cogn Behav Neurol. 2007;20:11-14.
59. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: Meta-analysis of randomized controlled trials. Drug Saf. 2010;33:147-161.